Victoza (liraglutide) is a prescription drug used to help manage type 2 diabetes and reduce the risk of certain diabetes-related heart problems. Victoza is given as a daily injection under the skin.

The primary focus was on GLP-1 agonists, including semaglutide and liraglutide, while a secondary focus was placed on officially approved alcohol use disorder medications, such as naltrexone ...

RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...

This study provides valuable guidance for doctors and patients when choosing diabetes medications. It confirms that ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

Bengaluru: Biocon Limited, an innovation-led global biopharmaceutical company, has announced the launch of its GLP-1 peptide, ...

Please provide your email address to receive an email when new articles are posted on . Liraglutide may improve outcomes and prognosis after minor stroke/transient ischemic attack in patients with ...

Lexaria Bioscience (LEXX) has made a strategic business decision to further investigate the commercial opportunities and applications for a ...

KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that ...

This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the ...